Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17459
Full metadata record
DC FieldValueLanguage
dc.contributor.authorda Gama Duarte, Jessica-
dc.contributor.authorWoods, Katherine-
dc.contributor.authorAndrews, Miles C-
dc.contributor.authorBehren, Andreas-
dc.date2018-
dc.date.accessioned2018-04-17T05:57:21Z-
dc.date.available2018-04-17T05:57:21Z-
dc.date.issued2018-02-02-
dc.identifier.citationImmunology and cell biology 2018; 96(5): 497-506-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17459-
dc.description.abstractWithin the immune system multiple mechanisms balance the need for efficient pathogen recognition and destruction with the prevention of tissue damage by excessive, inappropriate or even self-targeting (auto)immune reactions. This immune homeostasis is a tightly regulated system which fails during tumor development, often due to the hijacking of its essential self-regulatory mechanisms by cancer cells. It is facilitated not only by tumor intrinsic properties, but also by the microbiome, host genetics and other factors. In certain ways many cancers can therefore be considered a rare failure of immune control rather than an uncommon or rare disease of the tissue of origin, as the acquisition of potentially oncogenic traits through mutation occurs constantly in most tissues during proliferation. Normally, aberrant cells are well-controlled by cell intrinsic (repair or apoptosis) and extrinsic (immune) mechanisms. However, occasionally oncogenic cells survive and escape control. Melanoma is one of the first cancer types where treatments aimed at restoring and enhancing an immune response to regain control over the tumor have been used with various success rates. With the advent of "modern" immunotherapeutics such as anti-CTLA-4 or anti-PD-1 antibodies that both target negative immune-regulatory pathways on immune cells resulting in durable responses in a proportion of patients, the importance of the interplay between the immune system and cancer has been established beyond doubt.-
dc.language.isoeng-
dc.subjectImmune homeostasis-
dc.subjectImmunotherapy-
dc.subjectMelanoma-
dc.titleThe good, the (not so) bad and the ugly of immune homeostasis in melanoma.-
dc.typeJournal Article-
dc.identifier.journaltitleImmunology and cell biology-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia-
dc.identifier.affiliationMD Anderson Cancer Center, University of Texas, Houston, TX, USA-
dc.identifier.doi10.1111/imcb.12001-
dc.identifier.orcid0000-0003-4289-5204-
dc.identifier.orcid0000-0001-5329-280X-
dc.identifier.pubmedid29392770-
dc.type.austinJournal Article-
dc.type.austinReview-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.